P1, N=5, Not yet recruiting, Assistance Publique Hopitaux De Paris

P1, N=40, Completed, Cugene Inc. | Active, not recruiting --> Completed

The biomarker data supported the mechanism of action involving the upregulation of CD8+ T cells and NK cells. ClinicalTrials.gov Identifier: NCT05104567.

P1, N=23, Terminated, Cullinan Therapeutics Inc. | N=86 --> 23 | Trial completion date: Jun 2028 --> Jun 2026 | Recruiting --> Terminated | Trial primary completion date: Jun 2028 --> Jun 2026; Company decision

P1/2, N=30, Recruiting, The Methodist Hospital Research Institute

P1/2, N=124, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Jan 2030 | Trial primary completion date: Jan 2027 --> Jan 2029

P1/2, N=8, Terminated, University of Wisconsin, Madison | Trial completion date: Aug 2026 --> Dec 2025 | Active, not recruiting --> Terminated; Administrative

P2, N=180, Recruiting, Philogen S.p.A. | Not yet recruiting --> Recruiting | Initiation date: Feb 2026 --> Jun 2026

P1/2, N=25, Active, not recruiting, Alexander B Olawaiye, MD | Recruiting --> Active, not recruiting | N=70 --> 25 | Trial completion date: Dec 2027 --> Dec 2030 | Trial primary completion date: Dec 2025 --> May 2030

TFH-type lymphomas were associated with higher FOXP3-positive cell density than selected non-TFH-type comparators. DD treatment may be associated with changes in tissue immune infiltrates and peripheral CD8/TCR Vβ skewing in responding cases, although these findings remain exploratory and do not establish causality.

P1/2, N=2, Terminated, University Hospital, Bordeaux | Completed --> Terminated; target number of inclusion not reached

Pegenzileukin in combination with cemiplimab at the RP2D of 16 µg/kg showed a manageable safety profile and promising translational data supporting its mechanism of action.